肽咪胍啶酮联合化疗治疗难治复发性非霍奇金淋巴瘤

The efficacy of thalidomide in combination with chemotherapy in refractory recurrent non-Hodgkin lymphoma

目的观察肽咪胍啶酮(thalidom ide商品名:反应停)联合化疗在难治复发非何杰金淋巴瘤(NHL)治疗中的疗效及不良反应。方法治疗采用化疗联合反应停。应用ELISA方法测定32例患者治疗前后血清血管内皮细胞生长因子(VEGF)浓度;用凝血因子VIII相关抗原免疫组化染色法,观察骨髓微血管密度(MVD)。根据统一疗效标准判断疗效为完全缓解(CR)、部分缓解(PR)、稳定(NC)和进展(PD)。结果32例NHL患者CR 9例,PR 12例,NC 5例,PD 4例,总有效率71.8%,无不能耐受的不良反应。MVD、VEGF治疗前后相比差异均有显著性。结论反应停联合化疗治疗复发难治NHL疗效较好,是一种有效、值得探索的新方法。

Aim To study the therapeutic and adverse effects of thalidomide in combination with chemotherapy for the treatment of refractory recurrent non - Hodgkin lymphoma（NHL）. Methods 32 patients with refractory recurrent NHL received thalidomide combined with chemotherapy. The concentrations of serum vascular endothelial growth factor（VEGF） before and after therapy were measured with ELISA method, and bone marrow microvascular densities （MVD） before and after therapy were counted after coagulation - factor-Ⅷ-related-antigen immunohistochemical staining. According to the total efficacy standard,the therapeutic effects were classified as complete remission （CR） , partial remission （PR） , no change （NC） and progressing disease （PD）. Results The numbers of patients with CR, PR, NC and PD were 9,12,5,4 respectively. The total effectiveness rate was 71.8%. There were no unstandable adverse effects. The concentrations of VEGF and the counts of MVD after treatment were significantly lower than before （ P 〈 0.05 ）. Conclusions Thalidomide in combination with chemotherapy is an effective new approach to treating patients with refractory recurrent NHL.